OCA
CMPX icon

Octagon Capital Advisors’s Compass Therapeutics CMPX Stock Holding History

Octagon Capital Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-240,000
Closed -$761K – 25
2021
Q4 		$761K Buy
+240,000
New +$796K 0.15% 28

Other funds holding CMPX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Octagon Capital Advisors's CMPX Position: Q1 2022 in Review

Octagon Capital Advisors sold out of Compass Therapeutics (CMPX) in Q1 2022, closing a stake of 240,000 shares — an estimated $761K sold.

Octagon Capital Advisors first reported a position in CMPX in Q4 2021 and held it in 1 quarter. The position peaked at $761K in Q4 2021. 34 funds tracked by Wall St. Rank hold CMPX as of Q1 2022.

  • Octagon Capital Advisors reported no remaining Compass Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Octagon Capital Advisors sold 240,000 Compass Therapeutics shares in Q1 2022, an estimated $761K.
  • Octagon Capital Advisors first reported a position in Compass Therapeutics in Q4 2021 and held it in 1 quarter.
  • Octagon Capital Advisors's Compass Therapeutics position peaked at $761K in Q4 2021.
  • 34 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2022.

Based on Octagon Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.